A new antibody drug to restore the retina’s protective barrier
Official title: Investigation of a first-in-class Frizzled4/LRP5 agonist in retinal disease models
Funded at University of Minnesota · NIH-11249977 · Data updated 2026-11-12
This project tests a novel antibody designed to boost a natural signaling pathway to strengthen the retina’s protective barrier for people with retinal diseases that cause leaking or inflammation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | January 1, 2022 |
| Project end | December 31, 2026 |
| Funding year | 2026 |
| Award (this year) | $453,631 |
| NIH project number | 5R01EY033316-05 |
| Project ID | NIH-11249977 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with retinal conditions linked to blood‑retina barrier breakdown—such as diabetic retinopathy, wet age‑related macular degeneration, familial exudative vitreoretinopathy, or retinopathy of prematurity—would be the likely candidates for related future trials.
✕Less likely to help
Patients whose vision loss is primarily due to long‑standing scarring, non‑barrier causes, or unrelated eye diseases may not benefit from this therapy.
What this research studies
Researchers are developing a first‑in‑class antibody that mimics natural Norrin/WNT signals to activate the FZD4/LRP5 pathway and support the blood‑retina barrier. Lab experiments in cells will check how the antibody causes receptor complexes to form and turn on protective beta‑catenin signaling. The team will also test the antibody in multiple mouse models that mimic different types of retinal barrier defects. The goal is to see whether the antibody can reduce leakage and inflammation and restore normal transport across the barrier as a step toward future patient trials.
Why it matters
Potential benefit: If successful, this approach could repair the blood‑retina barrier, reduce fluid leakage and inflammation, and help prevent vision loss in several retinal vascular diseases.
How similar studies have gone: Basic research has shown Norrin/WNT signaling helps maintain blood‑CNS barriers, but using a therapeutic FZD4/LRP5 agonist like this antibody is novel and largely untested in humans.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Junge, Harald — University of Minnesota
- Study coordinator: Junge, Harald
Related research
Other NIH-funded projects on the same topics.
-
Integrative Curation of Clinically Relevant Variants in X-Linked Inherited Retinal Disease Genes
A project to expand expert review of genetic variants linked to X‑linked inherited retinal diseases so patients can access gene therapies.
-
Intravitreal gene therapy for inherited retinal disease
A specialized gene therapy approach delivered inside the eye is being studied to help children with inherited retinal diseases maintain or improve vision.
-
Retinal Disease: Molecular Basis and Pathophysiology
A gene mutation linked to retinal disease is studied to understand how it changes cellular pathways and leads to vision problems.
-
Genes that change how inherited retinal disorders behave
This work looks for other genes that change how CRB1-related inherited retinal diseases affect children and adults who carry CRB1 mutations.
-
Eye-injection gene therapy for inherited retinal disease
A gene therapy delivered by an injection into the eye aims to treat inherited forms of retinal degeneration, including in children.
-
Clear genetic answers for X-linked inherited retinal diseases
Building a trusted catalog of gene changes linked to X-linked inherited retinal diseases so people can get more accurate genetic diagnoses and access gene therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.